Stay updated on Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Sign up to get notified when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.

Latest updates to the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page
- Check7 days agoNo Change Detected
- Check14 days agoChange DetectedThe Study Details page now states that no participants are being recruited, reflecting the current enrollment status. New help sections 'How to Read a Study Record', 'Common Questions', and 'How to Join a Study' appear, and the Intervention/Treatment header is updated under Revision: v3.6.0, replacing the previous label.SummaryDifference0.4%

- Check21 days agoChange DetectedThe page footer now shows Revision: v3.5.5, replacing the previous v3.5.4, indicating a small update to the page rendering.SummaryDifference0.0%

- Check42 days agoChange DetectedThe page revision was updated from v3.5.3 to v3.5.4, indicating a deployed update to the ClinicalTrials.gov entry.SummaryDifference0.0%

- Check64 days agoChange DetectedThe page’s footer revision label has been updated from v3.5.2 to v3.5.3, reflecting a site software/version change rather than a change to the clinical trial record.SummaryDifference0.0%

- Check71 days agoChange DetectedRevision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check93 days agoChange DetectedAdrenal cortex carcinoma was added as a lay term for Adrenocortical Carcinoma in the Conditions section.SummaryDifference0.0%

Stay in the know with updates to Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Nivolumab+Ipilimumab in Rare GU Tumors Clinical Trial page.